No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes

Godbout, Ariane; Hammana, I.; Potvin, Stéphanie; Mainville, Darcy J; Räkel, Agnès; Berthiaume, Yves; Chiasson, J. L.; Coderre, Lise; Rabasa‐Lhoret, Rémi

doi:10.1016/j.diabet.2008.05.010

Cited by 69 publications

(56 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study further demonstrated that there was a low degree of correlation between HbA1c and glucose tolerance status [22]. The Table 4 Predictors of a positive screening test (HbA1c ≥ 5.8%) from the validation study.…”

Section: Discussionmentioning

confidence: 93%

HbA1c as a screening tool for cystic fibrosis related diabetes

Burgess

Bridges

Banya

et al. 2016

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

HbA1c as a screening tool for cystic fibrosis related diabetes

Burgess

Bridges

Banya

et al. 2016

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…Studies have shown a weak correlation between HbA1c and the degree of glucose tolerance. However, when HbA1c yields a high result, it should be taken into consideration in the diagnosis (20,21).…”

Section: Definition and Diagnosis Of Cfrd -An Evolving Visionmentioning

confidence: 99%

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Noronha

Calliari

Damaceno

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common recessive autosomal disease among Caucasian. Children with CF have benefitted from advances in medical and nutritional treatments, and this can be gleaned from the improvement in the survival of these patients. The increase in the survival rate brought with it the appearance of co-morbidities related to CF. Nowadays cystic fibrosis-related diabetes (CFRD) is considered the most common complication associated with CF. It can appear as early as infancy or adolescence, and its prevalence can be as high as 50% in adult patients. Because of its high prevalence, difficulties in early detection and the risks involved, in recent years several studies and consensuses have focused on this condition, adding information about the epidemiology, pathophysiology, prognosis and treatment of CFRD. The main aspects of these new concepts, as well as the current recommendations for its diagnosis and follow-up, will be presented in this study.

show abstract

“…Furthermore, glucose AUC considering the whole increment of glucose during OGTT and disposition index expressing the degree of b-cell compensation to reduced insulin sensitivity (20) appear to be better metabolic indicators of future glucose tolerance status than the more often used 2-h glucose and HbA1c. As others have argued (11, 13), we believe that standard OGTT criteria considering fasting and 2-h post-load (11,(21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system

Schiaffini

Baratto

Russo

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

A long pre-diabetic phase of abnormal glucose tolerance is described in subjects with cystic fibrosis (CF) since childhood. Objective: The aims of the study were to compare oral glucose tolerance test (OGTT) and continuous glucose monitoring system (CGMS) in the diagnosis of altered glucose metabolism, and to longitudinally evaluate the role of CGMS in predicting glucose metabolism deterioration in children with CF. Methods: Seventeen children with CF and 14 controls were enrolled (mean age 13.3G3.0 years). All subjects underwent OGTT and CGMS registration. On the basis of OGTT, children were classified as normal glucose tolerance, impaired glucose tolerance (IGT), IGT plus at least one glucose value above 200 mg/dl at intermediate OGTT points (IGTC200) and CF-related diabetes (CFRD). HbA1c, glucose area under the curve, insulin sensitivity, and insulinogenic and disposition indexes were also considered. Subjects with CF underwent another OGTT after 2.5 years. Results: Baseline OGTT revealed 3/17 (7.6%) children with CF with at least one glucose value above 200 mg/dl (1 CFRD and 2 IGTC200), while CGMS revealed 6/17 (35.3%) children with glucose excursions above 200 mg/dl (PZ0.010). None of the controls showed glucose over 200 mg/dl either at OGTT or at CGMS. At the 2.5-year follow-up OGTT, all the six subjects who had diabetic glucose excursion (i.e. O200 mg/dl) at baseline CGMS presented IGTC200 or CFRD. In logistic regression analysis, CGMS diabetic excursion was the strongest predictor of IGTC200 and CFRD (P!0.001). Conclusions: CGMS could be a useful tool to predict glucose metabolism derangements in children affected by CF.

show abstract

No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes

Cited by 69 publications

References 30 publications

HbA1c as a screening tool for cystic fibrosis related diabetes

HbA1c as a screening tool for cystic fibrosis related diabetes

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system

Contact Info

Product

Resources

About